CY1116117T1 - Σταθεροποιημενα πολυπεπτιδια αυξητικου παραγοντα ινσουλινομορφου της ινσουλινης - Google Patents

Σταθεροποιημενα πολυπεπτιδια αυξητικου παραγοντα ινσουλινομορφου της ινσουλινης

Info

Publication number
CY1116117T1
CY1116117T1 CY20151100260T CY151100260T CY1116117T1 CY 1116117 T1 CY1116117 T1 CY 1116117T1 CY 20151100260 T CY20151100260 T CY 20151100260T CY 151100260 T CY151100260 T CY 151100260T CY 1116117 T1 CY1116117 T1 CY 1116117T1
Authority
CY
Cyprus
Prior art keywords
insulin
informational
stabilized
polypeptides
growth
Prior art date
Application number
CY20151100260T
Other languages
English (en)
Inventor
David Jonathan Glass
Mara Fornaro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116117(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1116117T1 publication Critical patent/CY1116117T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Η εφεύρεση αναφέρεται στα σταθεροποιημένα πολυπεπτίδια που έχουν μια αλληλουχία IGF-1 ή IGF-2 και μια αλληλουχία πεπτιδίου-Ε, όπου η φυσική, φυσιολογική διάσπαση του πεπτιδίου-Ε από τον IGF εμποδίζεται.
CY20151100260T 2006-06-09 2015-03-13 Σταθεροποιημενα πολυπεπτιδια αυξητικου παραγοντα ινσουλινομορφου της ινσουλινης CY1116117T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81234906P 2006-06-09 2006-06-09
US86224406P 2006-10-20 2006-10-20
US89718707P 2007-01-24 2007-01-24
EP07798148.8A EP2032155B1 (en) 2006-06-09 2007-06-06 Stabilized insulin-like growth factor polypeptides

Publications (1)

Publication Number Publication Date
CY1116117T1 true CY1116117T1 (el) 2017-02-08

Family

ID=38801859

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100260T CY1116117T1 (el) 2006-06-09 2015-03-13 Σταθεροποιημενα πολυπεπτιδια αυξητικου παραγοντα ινσουλινομορφου της ινσουλινης

Country Status (33)

Country Link
US (4) US20100173839A1 (el)
EP (2) EP2032155B1 (el)
JP (2) JP2009539805A (el)
KR (1) KR101459789B1 (el)
AR (1) AR061242A1 (el)
AU (2) AU2007255419A1 (el)
BR (2) BRPI0712052A2 (el)
CA (2) CA2653781A1 (el)
CL (1) CL2007001614A1 (el)
CR (2) CR10432A (el)
CY (1) CY1116117T1 (el)
DK (2) DK2032155T3 (el)
EC (1) ECSP088949A (el)
ES (1) ES2529261T3 (el)
GT (1) GT200800273A (el)
HK (1) HK1126429A1 (el)
HR (1) HRP20150326T1 (el)
IL (1) IL195156A (el)
JO (1) JO2968B1 (el)
MA (1) MA30503B1 (el)
MX (2) MX2008015657A (el)
MY (1) MY147856A (el)
NO (2) NO20085183L (el)
NZ (2) NZ572548A (el)
PE (1) PE20080715A1 (el)
PL (1) PL2032155T3 (el)
PT (1) PT2032155E (el)
RU (1) RU2477287C2 (el)
SI (1) SI2032155T1 (el)
TN (1) TNSN08509A1 (el)
TW (1) TWI427084B (el)
UA (1) UA97953C2 (el)
WO (2) WO2007146689A2 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318355A1 (en) * 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
UA97953C2 (uk) 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту
ES2830350T3 (es) 2008-05-07 2021-06-03 Biomarin Pharm Inc Péptidos de dirección lisosómica y usos de los mismos
EA201100741A1 (ru) * 2008-11-10 2012-01-30 Новартис Аг Антитела к модифицированным пептидам ифр-1/е человека
WO2010088502A2 (en) * 2009-01-30 2010-08-05 The Regents Of The University Of California Insulin-like growth factor signaling and integrin
MA33279B1 (fr) 2009-04-27 2012-05-02 Novartis Ag Compositions et procédés pour l'augmentation de la croissance des muscles
UA103104C2 (ru) * 2009-07-22 2013-09-10 Ипсен Фарма С.А.С. Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
WO2011057249A2 (en) * 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
JP2011160696A (ja) * 2010-02-08 2011-08-25 Novartis Ag 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
WO2012116203A1 (en) 2011-02-23 2012-08-30 Massachusetts Institute Of Technology Water soluble membrane proteins and methods for the preparation and use thereof
US20140357558A1 (en) * 2011-06-24 2014-12-04 Cold Spring Harbor Laboratory Compositions and methods for treatment of spinal muscular atrophy
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
WO2014012025A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Igf-1 proteins and therapeutic uses thereof
JP6392245B2 (ja) * 2012-12-18 2018-09-19 ノバルティス アーゲー 遺伝子改変哺乳動物細胞における治療用タンパク質の産生
KR102182523B1 (ko) * 2012-12-18 2020-11-25 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
BR112016002198A2 (pt) 2013-08-14 2017-09-12 Novartis Ag métodos de tratamento de miosite por corpos de inclusão esporádica
WO2015049630A1 (en) 2013-10-02 2015-04-09 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) * 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
WO2015095650A1 (en) * 2013-12-19 2015-06-25 Puretein Bioscience Llc. Methods for treating an animal
WO2015111008A2 (en) 2014-01-27 2015-07-30 Novartis Ag Biomarkers predictive of muscle atrophy, method and use
WO2015149085A2 (en) * 2014-03-27 2015-10-01 Massachusetts Institute Of Technology Warer-soluble trans-membrane proteins and methods for the preparation and use thereof
US10373702B2 (en) 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
WO2016126924A1 (en) * 2015-02-04 2016-08-11 Puretein Bioscience Llc Methods for increasing performance characteristics in offspring
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
KR102628323B1 (ko) 2017-03-24 2024-01-22 노바르티스 아게 심장질환 예방 및 치료 방법
JP6691503B2 (ja) * 2017-04-13 2020-04-28 任天堂株式会社 ゲームプログラム、ゲーム処理制御方法、およびゲーム装置
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TW202342509A (zh) * 2022-01-31 2023-11-01 國立大學法人信州大學 以IGF1R為標的之pre-pro前驅體型嵌合抗原受體表現細胞

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JPH0720993B2 (ja) * 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
DE3852636T2 (de) 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
WO1993023067A1 (en) * 1992-05-08 1993-11-25 Thomas Jefferson University Igf-1 analogs
AU1178395A (en) 1993-11-12 1995-05-29 North Shore University Hospital Research Corporation Method of treating muscular dystrophy
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
GB9605124D0 (en) * 1996-03-11 1996-05-08 Royal Free Hosp School Med Method of treating muscular disorders
US7118752B2 (en) * 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
GB9926968D0 (en) * 1999-11-15 2000-01-12 Univ London Treatment of neurological disorders
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
DK1456360T3 (en) * 2001-04-19 2015-08-31 Scripps Research Inst Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
WO2004039956A2 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7355018B2 (en) * 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
AU2006203882B2 (en) 2005-01-07 2011-05-12 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
EP1868637A1 (en) 2005-03-18 2007-12-26 UCL Business PLC Mechano growth factor peptides and their use
JP4713579B2 (ja) 2005-03-31 2011-06-29 パイオニア株式会社 アプリケーションプログラム
UA97953C2 (uk) 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту

Also Published As

Publication number Publication date
HRP20150326T1 (hr) 2015-04-24
CA2653781A1 (en) 2007-12-13
IL195156A (en) 2014-07-31
EP2032155B1 (en) 2014-12-24
CR20160115A (es) 2016-06-14
BRPI0712147A2 (pt) 2012-02-22
ECSP088949A (es) 2009-01-30
DK200900016A (da) 2009-01-06
RU2008151511A (ru) 2010-07-20
CA2654944A1 (en) 2007-12-21
NO20085183L (no) 2009-03-09
NO20085184L (no) 2009-03-03
PT2032155E (pt) 2015-04-07
WO2007146689A9 (en) 2010-12-16
KR20090027197A (ko) 2009-03-16
JP2009539805A (ja) 2009-11-19
BRPI0712052A2 (pt) 2012-01-10
JP2009539383A (ja) 2009-11-19
TWI427084B (zh) 2014-02-21
US20170066808A9 (en) 2017-03-09
MX2008015726A (es) 2008-12-19
TNSN08509A1 (en) 2010-04-14
PL2032155T3 (pl) 2015-05-29
ES2529261T3 (es) 2015-02-18
NZ572548A (en) 2011-06-30
WO2007141309A3 (en) 2008-05-29
IL195156A0 (en) 2011-08-01
RU2477287C2 (ru) 2013-03-10
MA30503B1 (fr) 2009-06-01
MY147856A (en) 2013-01-31
TW200835698A (en) 2008-09-01
AR061242A1 (es) 2008-08-13
WO2007146689A3 (en) 2008-04-10
MX2008015657A (es) 2009-02-04
KR101459789B1 (ko) 2014-11-07
US20100173839A1 (en) 2010-07-08
JO2968B1 (en) 2016-03-15
WO2007146689A2 (en) 2007-12-21
AU2007257936B2 (en) 2011-05-26
WO2007141309A2 (en) 2007-12-13
CA2654944C (en) 2017-01-03
SI2032155T1 (sl) 2015-04-30
PE20080715A1 (es) 2008-07-25
US8343918B2 (en) 2013-01-01
US20130059779A1 (en) 2013-03-07
US20140235538A1 (en) 2014-08-21
JP5290966B2 (ja) 2013-09-18
CL2007001614A1 (es) 2008-08-08
NZ572708A (en) 2011-11-25
AU2007257936A1 (en) 2007-12-21
EP2032154A2 (en) 2009-03-11
GT200800273A (es) 2009-09-16
AU2007255419A1 (en) 2007-12-13
HK1126429A1 (en) 2009-09-04
US8722621B2 (en) 2014-05-13
US20100234290A1 (en) 2010-09-16
DK2032155T3 (en) 2015-03-02
UA97953C2 (uk) 2012-04-10
EP2032155A2 (en) 2009-03-11
CR10432A (es) 2009-01-15

Similar Documents

Publication Publication Date Title
CY1116117T1 (el) Σταθεροποιημενα πολυπεπτιδια αυξητικου παραγοντα ινσουλινομορφου της ινσουλινης
BRPI0917535A8 (pt) uso de insulina de ação ultra rápida
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
AR053259A1 (es) Trigo con nuevo almidon y metodo para producirlo
ES2575906T3 (es) Composiciones y métodos de producir metionina
PA8811501A1 (es) Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
WO2007135665A3 (en) Flexible endoscope system and functionality
BR112014009418A2 (pt) macrociclos peptidomiméticos
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
MX2014001190A (es) Solucion inyectable de al menos insulina basal.
ATE557037T1 (de) Insulin derivate
PE20130511A1 (es) Formulaciones de insulina de accion prolongada
DOP2009000267A (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
PE20121361A1 (es) Antagonistas de pcsk9
AR080884A1 (es) Conjugados de insulina-sirna
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
EA201000327A1 (ru) Белок
ECSP12011577A (es) Produccion recombinante de péptidos
BR112012011467A2 (pt) forma glicosilada de análogo ao glp-1 antigênico.
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
AR113492A2 (es) Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla
ATE473758T1 (de) Her-2/neu multipeptidimpfstoff
NZ596501A (en) Casb7439 constructs
NO20084053L (no) Inhibering av tumorvekst